Effects of time to treatment initiation on outcomes for soft tissue sarcomas

被引:1
作者
Ryu, Jae Hong [1 ,3 ]
Rahman, Juma [2 ]
Deo, Shaneel [1 ]
Flint, Michael [1 ]
机构
[1] Cty Manukau Hlth, Middlemore Hosp, Dept Orthopaed Surg, Auckland, New Zealand
[2] Cty Manukau Hlth, Res & Evaluat Off, Auckland, New Zealand
[3] Middlemore Hosp, 100 Hosp Rd, Auckland 2025, New Zealand
关键词
extremities; humans; sarcoma; soft tissue neoplasms; time-to-treatment; RADIATION-THERAPY; IMPROVED SURVIVAL; SURGERY; CANCER; MANAGEMENT; EXTREMITY; RADIOTHERAPY; IMPACT;
D O I
10.1002/jso.27237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivesFew studies have investigated the effects of time to treatment initiation (TTI) for soft tissue sarcomas (STS). Our objective was to investigate the risk factors for prolonged TTI and the effects of prolonged TTI on local recurrence free survival (LRFS), distant metastasis free survival (DMFS), and disease specific survival (DSS). MethodPatients diagnosed with high-grade STS of the extremities and trunk from 2011 to 2020 were included. TTI was grouped into two groups (treatment provided in less than vs. more than or equal to 30 days). Two-year and 5-year survival probabilities were calculated for LRFS, DMFS, and DSS. Cox regression and Kruskal-Wallis tests in univariate analysis were conducted to find risk factors affecting TTI and the survival outcomes. ResultsIn the univariate analysis, diagnosis in the later 5-year period of the study, tumor size, and treatment modality were associated with prolonged TTI. TTI >= 30 days was associated with higher DMFS but no association was found with LRFS or DSS. Tumor size, surgical margins, and provision of surgery were associated with DSS. ConclusionDespite the delay in treatment for STS patients caused by the COVID-19 pandemic, our study showed TTI of more than 30 days does not negatively impact patients.
引用
收藏
页码:1174 / 1186
页数:13
相关论文
共 36 条
  • [21] Kumar D., 2017, Sarcoma: A Multidisciplinary Approach to Treatment, P23
  • [22] Radiation Therapy for Soft Tissue Sarcoma Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy
    Larrier, Nicole A.
    Czito, Brian G.
    Kirsch, David G.
    [J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 25 (04) : 841 - +
  • [23] Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada
    Malagon, Talia
    Yong, Jean H. E.
    Tope, Parker
    Miller, Wilson H., Jr.
    Franco, Eduardo L.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (08) : 1244 - 1254
  • [24] Ministry of Health, 2014, FAST CANC TREATM IND
  • [25] Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States
    Murphy, Colin T.
    Galloway, Thomas J.
    Handorf, Elizabeth A.
    Egleston, Brian L.
    Wang, Lora S.
    Mehra, Ranee
    Flieder, Douglas B.
    Ridge, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02) : 169 - +
  • [26] Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
    O'Sullivan, B
    Davis, AM
    Turcotte, R
    Bell, R
    Catton, C
    Chabot, P
    Wunder, J
    Kandel, R
    Goddard, K
    Sadura, A
    Pater, J
    Zee, B
    [J]. LANCET, 2002, 359 (9325) : 2235 - 2241
  • [27] Patients with an increased time to treatment initiation have a poorer overall survival after definitive surgery for localized high-grade soft-tissue sarcoma in the extremity or trunk REPORT FROM THE NATIONAL CANCER DATABASE
    Ogura, K.
    Fujiwara, T.
    Healey, J. H.
    [J]. BONE & JOINT JOURNAL, 2021, 103B (06) : 1142 - 1149
  • [28] Impact of cancer surgery slowdowns on patient survival during the COVID-19 pandemic: a microsimulation modelling study
    Parmar, Ambica
    Eskander, Antoine
    Sander, Beate
    Naimark, David
    Irish, Jonathan C.
    Chan, Kelvin K. W.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (11) : E408 - E414
  • [29] French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
    Penel, N.
    Bonvalot, S.
    Minard, V.
    Orbach, D.
    Gouin, F.
    Corradini, N.
    Brahmi, M.
    Marec-Berard, P.
    Briand, S.
    Gaspar, N.
    Llacer, C.
    Carrere, S.
    Dufresne, A.
    Le Cesne, A.
    Blay, J. Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (07) : 965 - 966
  • [30] Perry A, 2020, WHO classification of tumours series, V3